Bioequivalence Study Healthy Thai Volunteers Sitagliptin / Metformin Hydrochloride Tablets 50 mg / 1000 mg Bioequivalence Study Healthy Thai Volunteers
Conditions
Interventions
Each tablet contains Sitagliptin / Metformin Hydrochloride Tablets 50 mg / 1000 mg,Each tablet contains Sitagliptin / Metformin Hydrochloride Tablets 50 mg / 1000 mg
manufactured by Patheon Puerto R
Experimental Drug,Active Comparator Drug
Test ( T) Sitagliptin / Metformin Hydrochloride Tablets 50 mg / 1000 mg,Reference (R) : JANUMETTM Tablets 50 mg / 1000 mg
Sponsors
International Bio Service Co., Ltd
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1.Healthy Thai male or female subjects between the ages of 18 to 55 years. Subject must meet age requirements at the time of signing the initial informed consent and at the dosing day in Period 1. 2.Body mass index between 18.0 to 30.0 kg per square meter 3.Normal laboratory values, including vital signs and physical examination, for all parameters in clinical laboratory tests at screening. Any abnormalities from the normal or reference range will be carefully considered clinically relevant by the physician as individual cases, documented in study files prior to enrolling the subject in this study. 4.Non-smoker and non-consumer of nicotine containing products Non-smoker or non-consumer of nicotine containing products means any subject who has never smoked/consumed or stopped for at least 90 days. 5.Non-pregnant woman (negative pregnancy test) and not currently breast feeding. 6.Female subjects abstain from either hormonal methods of contraception (includingoral or transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone-releasing IUDs, postcoital contraceptive methods) or hormone replacement therapy for at least 28 days prior to check-in in Period 1. Injectable contraceptives e.g. Depo-Provera will be discontinued at least 6 months prior to check-in in Period 1. Subjects agree to use acceptable nonhormonal contraceptive methods such as condom, diaphragm, foams, jellies, or abstinence for at least 14 days prior to check-in in Period 1 until 7 days after the end of study in Period 2. Female subjects of non-childbearing potential must meet at least one of the following criteria prior to check-in in Period 1 Postmenopausal for at least 1 year or Surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) at least 6 months 7.Male subjects who are willing or able to use effective contraceptive e.g. condom or abstinence after check-in in Period 1 until 7 days after the end of study in Period 2. 8.Able to understand and voluntarily given written informed consent (signed and dated) by the subject prior to participating in this study. 9.Adequate venous access in both arms for the collection of a number of samples during the study 10. Willing to follow precautions during driving and when using machines due to dizziness and somnolence have been reported.
Exclusion criteria
Exclusion criteria: 1.History of allergic reaction or hypersensitivity to sitagliptin, metformin or any other component 2.History or evidence of clinically significant renal, hepatic, gastrointestinal, hematological (e.g. anemia), endocrine (e.g. hyper-/hypothyroid, diabetes), pulmonary or respiratory (e.g. asthma), cardiovascular (e.g. hyper-/hypotension), psychiatric (e.g. depression), neurologic (e.g. convulsant), allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) or any significant ongoing chronic medical illness 3.Have high risk for coronavirus infection based on risk assessment questionnaire or diagnosed as confirmed case of COVID-19 4.History about administration of COVID-19 vaccine within 30 days prior to checkin in each Period. 5.Have renal creatinine clearance (CrCl) < 45 mL/min based on serum creatinine results, using glomerular filtration rate (GFR; Cockcroft-Gault formula), at the screening laboratory test 6.History or evidence of acute or chronic metabolic acidosis including diabetic ketoacidosis or lactic acidosis 7.History or evidence of acute pancreatitis including fatal and non-fatal hemorrhagic or necrotizing pancreatitis 8.History or evidence of type 1 diabetes mellitus 9.History or evidence of heart failure 10.History or evidence of vitamin B12 deficiency 11.History or evidence of severe joint pain 12.History or evidence of bullous pemphigoid 13.Investigation with blood sample shows fasting blood glucose level less than 70 mg/dl or more than 99 mg/dl at screening 14.History or evidence of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption 15.History of sensitivity to heparin or heparin-induced thrombocytopenia 16.Any condition possibly affecting drug absorption e.g. gastrectomy, enterectomy, gastritis or duodenal or gastric ulceration other than appendectomy 17.History of diarrhea or vomiting within 24 hours prior to check-in in each period 18.History of problems with swallowing tablet or capsule 19.History or evidence of drug addict or investigation with urine sample shows a positive test for drug of abuse (morphine, marijuana or methamphetamine)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma Sitagliptin-Metformin concentration 0-72 hrs Cmax, AUC0-tlast and AUC 0-infinity | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma Sitagliptin-Metformin concentration 0-72.00 hours post-dose Tmax, t1/2 and The terminal elimination rate constant | — |
Countries
Thailand
Contacts
Public ContactPorrnee Puranajoti
International Bio Service Co., Ltd.
Outcome results
None listed